These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 26663151)

  • 1. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies.
    Iorio R
    Nat Rev Neurol; 2024 Feb; 20(2):84-98. PubMed ID: 38191918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MuSK myasthenia gravis as a manifestation of immune reconstitution inflammatory syndrome in an HIV-positive patient: a challenging diagnosis and therapeutic approach.
    Carmillo L; Congedo P; Caggiula M; Nuzzo MM; Fasano A
    Neurol Sci; 2023 Dec; 44(12):4575-4577. PubMed ID: 37594551
    [No Abstract]   [Full Text] [Related]  

  • 3. Efgartigimod improves triple-negative myasthenia gravis.
    Frangiamore R; Rinaldi E; Vanoli F; Andreetta F; Mantegazza R; Antozzi C
    Neurol Sci; 2024 Mar; 45(3):1307-1309. PubMed ID: 37875596
    [No Abstract]   [Full Text] [Related]  

  • 4. Bilateral hemidiaphragm atrophy and electrical myotonia in anti-muscle specific tyrosine kinase myasthenia gravis.
    Hansen ED; Mulvany-Robbins BE; Boon AJ; Beecher G
    Muscle Nerve; 2024 Feb; 69(2):239-241. PubMed ID: 38040912
    [No Abstract]   [Full Text] [Related]  

  • 5. Early-onset acquired myasthenia gravis secondary to anti-muscle-specific kinase autoantibodies.
    Yilmaz S; Gokben S; Serdaroglu G; Akcay A
    J Child Neurol; 2014 Jan; 29(1):108-10. PubMed ID: 23234677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle atrophy in muscle-specific tyrosine kinase (MuSK)-related myasthenia gravis.
    Moon SY; Lee SS; Hong YH
    J Clin Neurosci; 2011 Sep; 18(9):1274-5. PubMed ID: 21741841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcoidosis in a case of MuSK-positive myasthenia gravis.
    Spengos K; Vassilopoulou S; Christou Y; Manta P
    Neuromuscul Disord; 2008 Nov; 18(11):890-1. PubMed ID: 18815037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MuSK myasthenia gravis as a manifestation of immune restoration disease in an HIV-positive patient.
    Ragunathan K; Pathak B; Dahal K
    J Neurol; 2015 Mar; 262(3):777-8. PubMed ID: 25588730
    [No Abstract]   [Full Text] [Related]  

  • 9. Myotonic Discharges in Anti-MuSK Myasthenia.
    Joundi RA; Israelian G; Ghavanini A; Kassardjian CD
    Can J Neurol Sci; 2018 Nov; 45(6):707-708. PubMed ID: 30210011
    [No Abstract]   [Full Text] [Related]  

  • 10. Prepubertal muscle-specific kinase myasthenia with a long and benign natural course.
    Zouvelou V; Velonakis G
    Muscle Nerve; 2016 Jun; 53(6):989. PubMed ID: 26663151
    [No Abstract]   [Full Text] [Related]  

  • 11. Overcoming challenges in the diagnosis and treatment of myasthenia gravis.
    Evoli A; Iorio R; Bartoccioni E
    Expert Rev Clin Immunol; 2016; 12(2):157-68. PubMed ID: 26675896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis].
    Ohta R; Motomura M
    Rinsho Byori; 2014 Mar; 62(3):255-60. PubMed ID: 24800501
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.